News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

WellSpring Pharmaceutical Corporation And Medsite Pharmaceutical Services, LLC Complete E-Pharma Marketing Agreement To Promote Diuretic Drug, Dyrenium



10/19/2005 5:10:16 PM

NEPTUNE, N.J., March 3 /PRNewswire/ -- WellSpring Pharmaceutical Corporation and Medsite Pharmaceutical Services, LLC today jointly announced the completion of an agreement that provides WellSpring with Internet marketing capabilities to promote Dyrenium(R) to physicians online. Known as "e-pharma marketing," Medsite's suite of solutions provides WellSpring with direct access to over 400,000 physicians nationwide. WellSpring has partnered with Medsite because of this physician exposure and also because it does not maintain a traditional sales force to promote products. Medsite's i-detail(TM) is a cost-effective solution that enables WellSpring to reach physician target markets currently not being served by sales representatives. The drug being promoted by this system is Dyrenium, a diuretic agent used to treat edema (fluid retention) caused by congestive heart failure, liver cirrhosis, and other related diseases. Dyrenium participates in the US market for diuretic drugs which is projected to reach $2.2 billion by 2005. This segment of the cardiovascular drug market has an annual average growth rate of 10.6%.

"This `virtual' sales force concept is a cost-effective way for WellSpring to have a national sales presence to promote Dyrenium. Physicians should gain valuable educational benefits by learning about Dyrenium in a time-efficient, online environment," said Dr. Robert A. Vukovich, founder and CEO of WellSpring. Physicians are targeted by their demographics and emailed a detail explaining product information about Dyrenium and other Diuretic therapies. The initiatives focus in three-fold: educate physicians about Dyrenium, solicit feedback about current diuretic prescribing habits and offer product samples.

In harnessing robust technology with proprietary targeting analytics, WellSpring anticipates the i-detail program will increase marketing penetration in hard-to-reach physician segments and overcrowded medical practices. Sundeep Bhan, CEO of Medsite, Inc., commented, "WellSpring can be assured of a high response rate, as these physicians trust the Medsite brand. In addition to creating highly relevant content, our industry leading analytics and targeting capabilities ensure maximum exposure to the right physicians." In October 1999, WellSpring re-launched Dyrenium, a potassium- sparing diuretic indicated for the treatment of edema associated with congestive heart failure and cirrhosis of the liver. Congestive heart failure affects 5 million Americans and has an annual cost of sixty billion dollars to the health care system.

WellSpring Pharmaceutical Corporation is an innovative, specialty pharmaceutical company with a philosophy of developing and marketing niche products licensed or purchased from major pharmaceutical concerns. Dr. Robert A. Vukovich founded WellSpring in 1999 and currently serves as the CEO and President. WellSpring Pharmaceutical Corporation is headquartered in Neptune, New Jersey.

Medsite Pharmaceutical Services, LLC is a division of Medsite, Inc. Medsite is the leader in ethical and effective e-marketing. The company forms strong, long-lasting, and mutually beneficial relationships with physicians and the organizations that want to reach them. Medsite is a privately held, venture-backed company and was ranked number one as the fastest growing technology company in the Deloitte & Touche "Fast 50" (New York, 2001). Medsite is headquartered in New York City.

For further information, please contact: Pat Naffin WellSpring Pharmaceutical Corporation Neptune, NJ (732) 938-5885 or Joshua Mansbach KNB Communications for Medsite Inc. New York, NY (212) 505-2441

WellSpring Pharmaceutical Corporation

CONTACT: Pat Naffin, WellSpring Pharmaceutical Corporation,+1-732-938-5885; or Joshua Mansbach, KNB Communications for Medsite Inc.,+1-212-505-2441


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES